References
- Ludvigsson JF, Büsch K, Olén O, et al. Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. BMC Gastroenterol. 2017;17(1):1–8. doi:https://doi.org/10.1186/s12876-017-0578-9.
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390(10114):2769–2778. doi:https://doi.org/10.1016/S0140-6736(17)32448-0.
- Yadav V, Varum F, Bravo R, et al. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Transl Res. 2016;176:38–68. doi:https://doi.org/10.1016/j.trsl.2016.04.009.
- Liu T-C, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol. 2016;11:127–148. doi:https://doi.org/10.1146/annurev-pathol-012615-044152.
- de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256–261. doi:https://doi.org/10.1038/ng.3760.
- Chu H, Khosravi A, Kusumawardhani IP, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352(6289):1116–1120. doi:https://doi.org/10.1126/science.aad9948.
- Huang Y, Chen Z. Inflammatory bowel disease related innate immunity and adaptive immunity. Am J Transl Res. 2016;8(6):2490–2497.
- Feng T, Qin H, Wang L, et al. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J Immunol. 2011;186(11):6313–6318. doi:https://doi.org/10.4049/jimmunol.1001454.
- Panda SK, Colonna M. Innate lymphoid cells in mucosal immunity. Front Immunol. 2019;10:861. doi:https://doi.org/10.3389/fimmu.2019.00861.
- Harbord M, Eliakim R, Bettenworth D, European Crohn’s and Colitis Organisation [ECCO], et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. doi:https://doi.org/10.1093/ecco-jcc/jjx009.
- Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–774. doi:https://doi.org/10.1038/nri1457.
- Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflam Bowel Dis. 2009;15(9):1391–1396. doi:https://doi.org/10.1002/ibd.20910.
- Alexeev EE, Lanis JM, Kao DJ, et al. Microbiota-derived indole metabolites promote human and murine intestinal homeostasis through regulation of interleukin-10 receptor. Am J Pathol. 2018;188(5):1183–1194. doi:https://doi.org/10.1016/j.ajpath.2018.01.011.
- Wlodarska M, Luo C, Kolde R, et al. Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe. 2017;22(1):25–37. doi:https://doi.org/10.1016/j.chom.2017.06.007.
- Reigstad CS, Salmonson CE, Iii JFR, et al. Gut microbes promote colonic serotonin production through an effect of short‐chain fatty acids on enterochromaffin cells. FASEB J. 2015;29(4):1395–1403. doi:https://doi.org/10.1096/fj.14-259598.
- El-Merahbi R, Löffler M, Mayer A, Sumara G. The roles of peripheral serotonin in metabolic homeostasis. FEBS Lett. 2015;589(15):1728–1734. doi:https://doi.org/10.1016/j.febslet.2015.05.054.
- Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23(6):716–724. doi:https://doi.org/10.1016/j.chom.2018.05.003.
- Tashita C, Hoshi M, Hirata A, et al. Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice. World J Gastroenterol. 2020;26(9):918–932. doi:https://doi.org/10.3748/wjg.v26.i9.918.
- Coquerelle C, Oldenhove G, Acolty V, et al. Anti-CTLA-4 treatment induces IL-10-producing ICOS + regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut. 2009;58(10):1363–1373. doi:https://doi.org/10.1136/gut.2008.162842.
- Hubbard TD, Murray IA, Bisson WH, et al. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci Rep. 2015;5(1):12689–12613. doi:https://doi.org/10.1038/srep12689.
- Cavia-Saiz M, Muñiz Rodríguez P, Llorente Ayala B, et al. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Mol Biol Rep. 2014;41(4):2275–2279. doi:https://doi.org/10.1007/s11033-014-3080-2.
- Frydoonfar H, McGrath D, Spigelman A. Inhibition of proliferation of a colon cancer cell line by indole-3-carbinol. Colorectal Dis. 2002;4(3):205–207. doi:https://doi.org/10.1046/j.1463-1318.2002.00346.x.
- Shimada Y, Kinoshita M, Harada K, et al. Commensal bacteria-dependent indole production enhances epithelial barrier function in the colon. PLoS One. 2013;8(11):e80604. doi:https://doi.org/10.1371/journal.pone.0080604.
- Bertazzo A, Ragazzi E, Biasiolo M, et al. Enzyme activities involved in tryptophan metabolism along the kynurenine pathway in rabbits. Biochim Biophys Acta. 2001;1527(3):167–175. doi:https://doi.org/10.1016/S0304-4165(01)00165-9.
- Badawy AAB. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res. 2017;10:117864691769193. doi:https://doi.org/10.1177/1178646917691938.
- Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7087. doi:https://doi.org/10.1158/0008-5472.CAN-07-1872.
- Dai X, Zhu BT. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. J Histochem Cytochem. 2010;58(1):17–28. doi:https://doi.org/10.1369/jhc.2009.953604.
- Allegri G, Costa CVL, Bertazzo A, et al. Enzyme activities of tryptophan metabolism along the kynurenine pathway in various species of animals. Farmaco. 2003;58(9):829–836. doi:https://doi.org/10.1016/S0014-827X(03)00140-X.
- Michelhaugh SK, Guastella AR, Mittal S. Overview of the kynurenine pathway of tryptophan metabolism. In: Targeting the broadly pathogenic kynurenine pathway. Springer. 2015. pp. 3–9.
- Wang Q, Liu D, Song P, et al. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci (Landmark Ed). 2015;20:1116–1143. doi:https://doi.org/10.2741/4363.
- Campbell BM, Charych E, Lee AW, et al. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12. doi:https://doi.org/10.3389/fnins.2014.00012.
- Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Elsevier.
- Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25(1):131–117. doi:https://doi.org/10.1038/s41380-019-0414-4.
- Larkin PB, Sathyasaikumar KV, Notarangelo FM, et al. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochim Biophys Acta. 2016;1860(11 Pt A):2345–2354. doi:https://doi.org/10.1016/j.bbagen.2016.07.002.
- Wang SJ, Sharkey KA, McKay DM. Modulation of the immune response by helminths: a role for serotonin?Biosci Rep. 2018;38(5). doi:https://doi.org/10.1042/BSR20180027.
- Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–276. doi:https://doi.org/10.1016/j.cell.2015.02.047.
- Höglund E, Øverli Ø, Winberg S. Tryptophan metabolic pathways and brain serotonergic activity: a comparative review. Front Endocrinol (Lausanne). 2019;10:158. doi:https://doi.org/10.3389/fendo.2019.00158.
- Slominski A, Semak I, Pisarchik A, et al. Conversion of L‐tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett. 2002;511(1–3):102–106. doi:https://doi.org/10.1016/S0014-5793(01)03319-1.
- Sorgdrager FJH, Naudé PJW, Kema IP, et al. Tryptophan metabolism in inflammaging: from biomarker to therapeutic target. Front Immunol. 2019;10:2565. doi:https://doi.org/10.3389/fimmu.2019.02565.
- Harden JL, Lewis SM, Lish SR, et al. The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. J Allergy Clin Immunol. 2016;137(6):1830–1840. doi:https://doi.org/10.1016/j.jaci.2015.09.055.
- Strasser B, Becker K, Fuchs D, et al. Kynurenine pathway metabolism and immune activation: Peripheral measurements in psychiatric and co-morbid conditions. Neuropharmacology. 2017;112(Pt B):286–296., doi:https://doi.org/10.1016/j.neuropharm.2016.02.030.
- Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm (Vienna). 2012;119(2):197–209. doi:https://doi.org/10.1007/s00702-011-0681-y.
- Sforzini L, Nettis MA, Mondelli V, et al. Inflammation in cancer and depression: a starring role for the kynurenine pathway. Psychopharmacology. 2019;236(10):2997–3011.
- Croitoru-Lamoury J, Lamoury FMJ, Caristo M, et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One. 2011;6(2):e14698. doi:https://doi.org/10.1371/journal.pone.0014698.
- Du MX, Sotero-Esteva WD, Taylor MW. Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J Interferon Cytokine Res. 2000;20(2):133–142. doi:https://doi.org/10.1089/107999000312531.
- Chung DJ, Rossi M, Romano E, et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood J Am Soc Hematol. 2009;114(3):555–563. doi:https://doi.org/10.1182/blood-2008-11-191197.
- Chen W, Liang X, Peterson AJ, et al. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008;181(8):5396–5404. doi:https://doi.org/10.4049/jimmunol.181.8.5396.
- Nguyen NT, Kimura A, Nakahama T, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A. 2010;107(46):19961–19966. doi:https://doi.org/10.1073/pnas.1014465107.
- Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation . J Immunol. 2000;164(7):3596–3599. doi:https://doi.org/10.4049/jimmunol.164.7.3596.
- Wang X-F, Wang H-S, Wang H, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289(1-2):42–48. doi:https://doi.org/10.1016/j.cellimm.2014.02.005.
- François M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation . Mol Ther. 2012;20(1):187–195. doi:https://doi.org/10.1038/mt.2011.189.
- Lin Y, Yang X, Yue W, et al. Chemerin aggravates DSS-induced colitis by suppressing M2 macrophage polarization. Cell Mol Immunol. 2014;11(4):355–366. doi:https://doi.org/10.1038/cmi.2014.15.
- Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193–207. doi:https://doi.org/10.1016/j.it.2016.01.002.
- Cheng J-T, Deng Y-N, Yi H-M, et al. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis. 2016;5(2):e198. doi:https://doi.org/10.1038/oncsis.2016.7.
- Yang R, Gao N, Chang Q, et al. The role of IDO, IL‐10, and TGF‐β in the HCV‐associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol. 2019;91(2):265–271. doi:https://doi.org/10.1002/jmv.25083.
- Ala M. The footprint of kynurenine pathway in every cancer: A new target for chemotherapy. Eur J Pharmacol. 2021;896:173921. doi:https://doi.org/10.1016/j.ejphar.2021.173921.
- Campesato LF, Budhu S, Tchaicha J, et al. Blockade of IDO/TDO downstream effectors restricts cancer immune suppression. Am Assoc Immnol. 2019.
- Casen C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42(1):71–83.
- Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation?Nat Rev Gastroenterol Hepatol. 2017;14(10):573–584. doi:https://doi.org/10.1038/nrgastro.2017.88.
- Vila AV, Imhann F, Collij V, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 2018;10(472):eaap8914.
- Lee JS, Cella M, McDonald KG, et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol. 2011;13(2):144–151. doi:https://doi.org/10.1038/ni.2187.
- Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–385. doi:https://doi.org/10.1016/j.immuni.2013.08.003.
- Gutiérrez-Vázquez C, Quintana FJ. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity. 2018;48(1):19–33. doi:https://doi.org/10.1016/j.immuni.2017.12.012.
- Mizoguchi A, Yano A, Himuro H, et al. Clinical importance of IL-22 cascade in IBD. J Gastroenterol. 2018;53(4):465–474. doi:https://doi.org/10.1007/s00535-017-1401-7.
- Lamas B, Richard ML, Leducq V, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22(6):598–605. doi:https://doi.org/10.1038/nm.4102.
- Li G, Young KD. Indole production by the tryptophanase TnaA in Escherichia coli is determined by the amount of exogenous tryptophan. Microbiology (Reading). 2013;159(Pt 2):402–410. doi:https://doi.org/10.1099/mic.0.064139-0.
- Dodd D, Spitzer MH, Van Treuren W, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature. 2017;551(7682):648–652. doi:https://doi.org/10.1038/nature24661.
- Dicksved J, Schreiber O, Willing B, et al. Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. PLoS One. 2012;7(9):e46399. doi:https://doi.org/10.1371/journal.pone.0046399.
- Kokešová A, Frolová L, Kverka M, et al. Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol. 2006;51(5):478–484. doi:https://doi.org/10.1007/BF02931595.
- Bansal T, Alaniz RC, Wood TK, et al. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci U S A. 2010;107(1):228–233. doi:https://doi.org/10.1073/pnas.0906112107.
- Busbee PB, Menzel L, Alrafas H, et al. Indole-3-carbinol prevents colitis and associated microbial dysbiosis in an IL-22–dependent manner. JCI Insight. 2020;5(1):e127551. doi:https://doi.org/10.1172/jci.insight.127551.
- Alkarkoushi RR, Singh UP, Chatzistamou I, et al. Indole-3-carbinol ameliorates colonic inflammation in DSS-treated, Helicobacter muridarum-infected mice. J Immunol. 2019;202:185.4.
- Busbee PB, Alrafas H, Dopkins N, et al. Indole-3-carbinol prevents murine colitis development via an IL-22-dependent mechanism that regulates anti-microbial peptides and mucus production. J Immunol. 2019;202:192.12.
- Oh SH, Baek J, Liany H, et al. A synonymous variant in IL10RA affects RNA splicing in paediatric patients with refractory inflammatory bowel disease. J Crohns Colitis. 2016;10(11):1366–1371. doi:https://doi.org/10.1093/ecco-jcc/jjw102.
- Aoki R, Aoki-Yoshida A, Suzuki C, et al. Indole-3-pyruvic acid, an aryl hydrocarbon receptor activator, suppresses experimental colitis in mice. J Immunol. 2018;201(12):3683–3693. doi:https://doi.org/10.4049/jimmunol.1701734.
- Kabel AM, Omar MS, Alotaibi SN, et al. Effect of indole-3-carbinol and/or metformin on female patients with ulcerative colitis (premalignant condition): Role of oxidative stress, apoptosis and proinflammatory cytokines. J Cancer Res. 2017;5(1):1–8.
- Alexeev EE, Dowdell AS, Henen MA, et al. Microbial-derived indoles inhibit neutrophil myeloperoxidase to diminish bystander tissue damage. FASEB J. 2021;35(5):e21552. doi:https://doi.org/10.1096/fj.202100027R.
- Lai Y, Xue J, Liu C-W, et al. Serum metabolomics identifies altered bioenergetics, signaling cascades in parallel with exposome markers in Crohn’s disease. Molecules. 2019;24(3):449. doi:https://doi.org/10.3390/molecules24030449.
- Martin-Gallausiaux C, Marinelli L, Blottière HM, et al. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80(1):37–13., doi:https://doi.org/10.1017/S0029665120006916.
- Martin-Gallausiaux C, Larraufie P, Jarry A, et al. Butyrate produced by commensal bacteria down-regulates indolamine 2, 3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. Front Immunol. 2018;9:2838. doi:https://doi.org/10.3389/fimmu.2018.02838.
- Wang Y, Yuan X, Kang Y, et al. Tryptophan-kynurenine pathway as a novel link between gut microbiota and schizophrenia: A review. Trop J Pharm Res. 2019;18(5).
- Clarke G, Grenham S, Scully P, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18(6):666–673. doi:https://doi.org/10.1038/mp.2012.77.
- Zhu F, Guo R, Wang W, et al. Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice. Mol Psychiatry. 2020;25(11):2905–2918. doi:https://doi.org/10.1038/s41380-019-0475-4.
- Moloney GM, O’Leary OF, Salvo-Romero E, et al. Microbial regulation of hippocampal miRNA expression: Implications for transcription of kynurenine pathway enzymes. Behav Brain Res. 2017;334:50–54. doi:https://doi.org/10.1016/j.bbr.2017.07.026.
- Rudzki L, Ostrowska L, Pawlak D, et al. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. Psychoneuroendocrinology. 2019;100:213–222. doi:https://doi.org/10.1016/j.psyneuen.2018.10.010.
- Purton T, Staskova L, Lane MM, et al. Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: A systematic review and meta analysis. Neurosci Biobehav Rev. 2021;123:1–13., doi:https://doi.org/10.1016/j.neubiorev.2020.12.026.
- Török N, Tanaka M, Vécsei L. Searching for peripheral biomarkers in neurodegenerative diseases: The tryptophan-kynurenine metabolic pathway. IJMS. 2020;21(24):9338. doi:https://doi.org/10.3390/ijms21249338.
- Sun W, Guo Y, Zhang S, et al. Fecal microbiota transplantation can alleviate gastrointestinal transit in rats with high-fat diet-induced obesity via regulation of serotonin biosynthesis. Biomed Res Int. 2018;2018:8308671., doi:https://doi.org/10.1155/2018/8308671.
- Fung TC, Vuong HE, Luna CDG, et al. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. Nat Microbiol. 2019;4(12):2064–2073. doi:https://doi.org/10.1038/s41564-019-0540-4.
- Kwon YH, Wang H, Denou E, et al. Modulation of gut microbiota composition by serotonin signaling influences intestinal immune response and susceptibility to colitis. Cell Mol Gastroenterol Hepatol. 2019;7(4):709–728. doi:https://doi.org/10.1016/j.jcmgh.2019.01.004.
- El Aidy S, Ramsteijn AS, Dini-Andreote F, et al. Serotonin transporter genotype modulates the gut microbiota composition in young rats, an effect augmented by early life stress. Front Cell Neurosci. 2017;11:222. doi:https://doi.org/10.3389/fncel.2017.00222.
- Singhal M, Turturice BA, Manzella CR, et al. Serotonin transporter deficiency is associated with dysbiosis and changes in metabolic function of the mouse intestinal microbiome. Sci Rep. 2019;9(1):1–11. doi:https://doi.org/10.1038/s41598-019-38489-8.
- Thijssen AY, Mujagic Z, Jonkers DMAE, et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther. 2016;43(2):272–282. doi:https://doi.org/10.1111/apt.13459.
- Binienda A, Storr M, Fichna J, et al. Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome: a review. Curr Drug Targets. 2018;19(15):1774–1781. doi:https://doi.org/10.2174/1389450119666171227225408.
- Minderhoud IM, Oldenburg B, Schipper MEI, et al. Serotonin synthesis and uptake in symptomatic patients with Crohn’s disease in remission. Clin Gastroenterol Hepatol. 2007;5(6):714–720. doi:https://doi.org/10.1016/j.cgh.2007.02.013.
- Kidd M, Gustafsson BI, Drozdov I, et al. IL1β‐and LPS‐induced serotonin secretion is increased in EC cells derived from Crohn’s disease. Neurogastroenterol Motil. 2009;21(4):439–450. doi:https://doi.org/10.1111/j.1365-2982.2008.01210.x.
- Manzella CR, Jayawardena D, Pagani W, et al. Serum serotonin differentiates between disease activity states in Crohn’s patients. Inflamm Bowel Dis. 2020;26(10):1607–1618. doi:https://doi.org/10.1093/ibd/izaa208.
- Jørandli JW, Thorsvik S, Skovdahl HK, et al. The serotonin reuptake transporter is reduced in the epithelium of active Crohn’s disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2020;319(6):G761–G768. doi:https://doi.org/10.1152/ajpgi.00244.2020.
- Linden DR, Chen J-X, Gershon MD, et al. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G207–G216. doi:https://doi.org/10.1152/ajpgi.00488.2002.
- Li N, Ghia J-E, Wang H, et al. Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol. 2011;178(2):662–671. doi:https://doi.org/10.1016/j.ajpath.2010.10.028.
- Bischoff SC, Mailer R, Pabst O, et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice . Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G685–G695. doi:https://doi.org/10.1152/ajpgi.90685.2008.
- Linden DR, Foley KF, McQuoid C, et al. Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol Motil. 2005;17(4):565–574. doi:https://doi.org/10.1111/j.1365-2982.2005.00673.x.
- Salaga M, Binienda A, Piscitelli F, et al. Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. Biochem Pharmacol. 2019;161:37–51. doi:https://doi.org/10.1016/j.bcp.2019.01.001.
- Spohn SN, Bianco F, Scott RB, et al. Protective actions of epithelial 5-hydroxytryptamine 4 receptors in normal and inflamed colon. Gastroenterology. 2016;151(5):933–944. doi:https://doi.org/10.1053/j.gastro.2016.07.032.
- Guseva D, Holst K, Kaune B, et al. Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract. Inflamm Bowel Dis. 2014;20(9):1516–1529. doi:https://doi.org/10.1097/MIB.0000000000000150.
- Kim JJ, Bridle BW, Ghia J-E, et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol. 2013;190(9):4795–4804. doi:https://doi.org/10.4049/jimmunol.1201887.
- Motavallian A, Minaiyan M, Rabbani M, et al. Involvement of 5HT3 receptors in anti-inflammatory effects of tropisetron on experimental TNBS-induced colitis in rat. BioImpacts: BI. 2013;3(4):169.
- Motavallian A, Minaiyan M, Rabbani M, et al. Anti-inflammatory effects of alosetron mediated through 5-HT3 receptors on experimental colitis. Res Pharm Sci. 2019;14(3):228–236. doi:https://doi.org/10.4103/1735-5362.258489.
- Rapalli A, Bertoni S, Arcaro V, et al. Dual role of endogenous serotonin in 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Front Pharmacol. 2016;7:68. doi:https://doi.org/10.3389/fphar.2016.00068.
- Takamatsu M, Hirata A, Ohtaki H, et al. IDO1 plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice. J Immunol. 2013;191(6):3057–3064. doi:https://doi.org/10.4049/jimmunol.1203306.
- Gurtner GJ, Newberry RD, Schloemann SR, et al. Inhibition of indoleamine 2, 3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology. 2003;125(6):1762–1773. doi:https://doi.org/10.1053/j.gastro.2003.08.031.
- Ciorba MA, Bettonville EE, McDonald KG, et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol. 2010;184(7):3907–3916. doi:https://doi.org/10.4049/jimmunol.0900291.
- Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells . Stem Cells. 2006;24(2):386–398. doi:https://doi.org/10.1634/stemcells.2005-0008.
- Duijvestein M, Wildenberg ME, Welling MM, et al. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells. 2011;29(10):1549–1558. doi:https://doi.org/10.1002/stem.698.
- Shon W-J, Lee Y-K, Shin JH, et al. Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networks. Sci Rep. 2015;5:17305. doi:https://doi.org/10.1038/srep17305.
- Lanis JM, Alexeev EE, Curtis VF, et al. Tryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epithelia. Mucosal Immunol. 2017;10(5):1133–1144. doi:https://doi.org/10.1038/mi.2016.133.
- Lamas B, Natividad JM, Sokol H. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunol. 2018;11(4):1024–1038. doi:https://doi.org/10.1038/s41385-018-0019-2.
- Islam J, Sato S, Watanabe K, et al. Dietary tryptophan alleviates dextran sodium sulfate-induced colitis through aryl hydrocarbon receptor in mice. J Nutr Biochem. 2017;42:43–50. doi:https://doi.org/10.1016/j.jnutbio.2016.12.019.
- Kim CJ, Kovacs-Nolan JA, Yang C, et al. l-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis. J Nutr Biochem. 2010;21(6):468–475. doi:https://doi.org/10.1016/j.jnutbio.2009.01.019.
- Chen S, Wang M, Yin L, et al. Effects of dietary tryptophan supplementation in the acetic acid-induced colitis mouse model. Food Funct. 2018;9(8):4143–4152. doi:https://doi.org/10.1039/c8fo01025k.
- Ferdinande L, Demetter P, Perez-Novo C, et al. Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int J Immunopathol Pharmacol. 2008;21(2):289–295. doi:https://doi.org/10.1177/039463200802100205.
- Forrest CM, Youd P, Kennedy A, et al. Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease. J Biomed Sci. 2002;9(5):436–442. doi:https://doi.org/10.1007/BF02256538.
- Forrest CM, Gould SR, Darlington LG, et al. Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. Adv Exp Med Biol. 2003;527:395–400. doi:https://doi.org/10.1007/978-1-4615-0135-0_46.
- Zhou L, Chen H, Wen Q, et al. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24(6):695–701. doi:https://doi.org/10.1097/MEG.0b013e328351c1c2.
- Liu X, Zhou W, Zhang X, et al. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells. Int J Cancer. 2018;143(6):1516–1529. doi:https://doi.org/10.1002/ijc.31417.
- Dudzińska E, Szymona K, Kloc R, et al. Increased expression of kynurenine aminotransferases mRNA in lymphocytes of patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2019;12:1756284819881304. doi:https://doi.org/10.1177/1756284819881304.
- Wolf AM, Wolf D, Rumpold H, et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease . Clin Immunol. 2004;113(1):47–55. doi:https://doi.org/10.1016/j.clim.2004.05.004.
- Sofia MA, Ciorba MA, Meckel K, et al. Tryptophan metabolism through the kynurenine pathway is associated with endoscopic inflammation in ulcerative colitis. Inflamm Bowel Dis. 2018;24(7):1471–1480. doi:https://doi.org/10.1093/ibd/izy103.
- Gupta NK, Thaker AI, Kanuri N, et al. Serum analysis of tryptophan catabolism pathway: correlation with Crohn’s disease activity. Inflamm Bowel Dis. 2012;18(7):1214–1220. doi:https://doi.org/10.1002/ibd.21849.
- Arijs I, Wollants W-J, Clarke G, et al. P096 Analysis of the tryptophan metabolism and indoleamine 2, 3-dioxygenase expression (IDO) in patients with inflammatory bowel disease before and after infliximab treatment. J Crohn’s Colitis. 2014;8(Supplement_1):S102. doi:https://doi.org/10.1016/S1873-9946(14)60218-X.
- Nikolaus S, Schulte B, Al-Massad N, et al. Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases. Gastroenterology. 2017;153(6):1504–1516. doi:https://doi.org/10.1053/j.gastro.2017.08.028.
- Huhn M, Herrero San Juan M, Melcher B, et al. Inflammation-induced mucosal KYNU expression identifies human ileal Crohn’s disease. JCM. 2020;9(5):1360. doi:https://doi.org/10.3390/jcm9051360.
- Gausman V, Dornblaser D, Anand S, et al. Risk factors associated with early-onset colorectal cancer. Clin Gastroenterol Hepatol. 2020;18(12):2752–2759. e2. doi:https://doi.org/10.1016/j.cgh.2019.10.009.
- Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(5):475–484. doi:https://doi.org/10.1016/S2468-1253(20)30005-4.
- Bopanna S, Ananthakrishnan AN, Kedia S, et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(4):269–276. doi:https://doi.org/10.1016/S2468-1253(17)30004-3.
- Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. World J Gastroenterol. 2019;25(30):4148–4157. doi:https://doi.org/10.3748/wjg.v25.i30.4148.
- Engin AB. Helicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancer. World J Gastroenterol. 2015;21(12):3636. doi:https://doi.org/10.3748/wjg.v21.i12.3636.
- Crotti S, D’Angelo E, Bedin C, et al. Tryptophan metabolism along the kynurenine and serotonin pathways reveals substantial differences in colon and rectal cancer. Metabolomics. 2017;13(12):148. doi:https://doi.org/10.1007/s11306-017-1288-6.
- Gao Y-F, Peng R-Q, Li J, et al. The paradoxical patterns of expression of indoleamine 2, 3-dioxygenase in colon cancer. J Transl Med. 2009;7(1):71–78. doi:https://doi.org/10.1186/1479-5876-7-71.
- Liu C-Y, Huang TT, Chen JL, et al. Significance of kynurenine 3-monooxygenase expression in colorectal cancer. Front Oncol. 2021;11:664.
- Boros FA, Vécsei L. Immunomodulatory effects of genetic alterations affecting the kynurenine pathway. Front Immunol. 2019;10:2570. doi:https://doi.org/10.3389/fimmu.2019.02570.
- Pilotte L, Larrieu P, Stroobant V, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A. 2012;109(7):2497–2502. doi:https://doi.org/10.1073/pnas.1113873109.
- Zheng X, Koropatnick J, Li M, et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006;177(8):5639–5646. doi:https://doi.org/10.4049/jimmunol.177.8.5639.
- Wang D, Saga Y, Mizukami H, et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol. 2012;40(4):929–934. doi:https://doi.org/10.3892/ijo.2011.1295.
- Maleki Vareki S, Chen D, Di Cresce C, et al. IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells. PLoS One. 2015;10(11):e0143435. doi:https://doi.org/10.1371/journal.pone.0143435.
- Ogawa K, Hara T, Shimizu M, et al. (-) (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. Oncol Lett. 2012;4(3):546–550. doi:https://doi.org/10.3892/ol.2012.761.
- Wu D, Zhu Y. Role of kynurenine in promoting the generation of exhausted CD8+ T cells in colorectal cancer. Am J Transl Res. 2021;13(3):1535–1547.
- Bordon Y. TOX for tired T cells. Nat Rev Immunol. 2019;19(8):476–476. doi:https://doi.org/10.1038/s41577-019-0193-9.
- Santhanam S, Alvarado D, Khouri A, et al. PD-236 defining the signaling pathways and functional role for kynurenine metabolites in the normal and neoplastic colon epithelium. Inflamm Bowel Dis. 2017;23
- Bishnupuri KS, Alvarado DM, Khouri AN, et al. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis. Cancer Res. 2019;79(6):1138–1150. doi:https://doi.org/10.1158/0008-5472.CAN-18-0668.
- Thaker AI, Rao MS, Bishnupuri KS, et al. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology. 2013;145(2):416–425. doi:https://doi.org/10.1053/j.gastro.2013.05.002.
- Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol. 2010;30(6):1411–1420. doi:https://doi.org/10.1128/MCB.01384-09.
- Satoh K, Yachida S, Sugimoto M, et al. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc Natl Acad Sci U S A. 2017;114(37):E7697–E7706. doi:https://doi.org/10.1073/pnas.1710366114.
- Venkateswaran N, Lafita-Navarro MC, Hao Y-H, et al. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev. 2019;33(17-18):1236–1251. doi:https://doi.org/10.1101/gad.327056.119.
- Niwa Y, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24(42):6406–6417. doi:https://doi.org/10.1038/sj.onc.1208788.
- Wang S-W, Sun Y-M. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 2014;44(4):1032–1040. doi:https://doi.org/10.3892/ijo.2014.2259.
- Slattery ML, Lundgreen A, Kadlubar SA, et al. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog. 2013;52(2):155–166. doi:https://doi.org/10.1002/mc.21841.
- Campia I, Buondonno I, Castella B, et al. An autocrine cytokine/JAK/STAT-signaling induces kynurenine synthesis in multidrug resistant human cancer cells. PLoS One. 2015;10(5):e0126159. doi:https://doi.org/10.1371/journal.pone.0126159.
- Fugmann SD. The origins of the Rag genes-from transposition to V (D) J recombination. Semin Immunol. 2010;22(1):10–6. doi:https://doi.org/10.1016/j.smim.2009.11.004.
- Walczak K, Turski WA, Rzeski W. Kynurenic acid enhances expression of p21 Waf1/Cip1 in colon cancer HT-29 cells. Pharmacol Rep. 2012;64(3):745–750. doi:https://doi.org/10.1016/S1734-1140(12)70870-8.
- Singh SK, Banerjee S, Acosta EP, et al. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 2017;8(10):17216–17228. doi:https://doi.org/10.18632/oncotarget.15303.
- Singh K, Dong Q, Koul S, Koul HK. TET increases p27Kip1 protein stability and p21WAF1/Cip1 promoter activity to block deregulated cell cycle progression in pancreatic cancer cells. AACR. 2018.
- Walczak K, Turski WA, Rajtar G. Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways. Amino Acids. 2014;46(10):2393–2401. doi:https://doi.org/10.1007/s00726-014-1790-3.
- Walczak K, Dąbrowski W, Langner E, et al. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol. 2011;46(7-8):903–912. doi:https://doi.org/10.3109/00365521.2011.579159.
- Seok S-H, Ma Z-X, Feltenberger JB, et al. Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J Biol Chem. 2018;293(6):1994–2005. doi:https://doi.org/10.1074/jbc.RA117.000631.
- Díaz-Díaz CJ, Ronnekleiv-Kelly SM, Nukaya M, et al. The aryl hydrocarbon receptor is a repressor of inflammation-associated colorectal tumorigenesis in mouse. Ann Surg. 2016;264(3):429–436. doi:https://doi.org/10.1097/SLA.0000000000001874.
- Plate AY, Gallaher DD. Effects of indole-3-carbinol and phenethyl isothiocyanate on colon carcinogenesis induced by azoxymethane in rats. Carcinogenesis. 2006;27(2):287–292. doi:https://doi.org/10.1093/carcin/bgi210.
- Nakamura Y, Yogosawa S, Izutani Y, et al. A combination of indole-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer. 2009;8(1):100–115. doi:https://doi.org/10.1186/1476-4598-8-100.
- Kanehara K, Ohnuma S, Kanazawa Y, et al. The indole compound MA-35 attenuates tumorigenesis in an inflammation-induced colon cancer model. Sci Rep. 2019;9(1):1–13. doi:https://doi.org/10.1038/s41598-019-48974-9.
- Ronnekleiv-Kelly SM, Nukaya M, Díaz-Díaz CJ, et al. Aryl hydrocarbon receptor-dependent apoptotic cell death induced by the flavonoid chrysin in human colorectal cancer cells. Cancer Lett. 2016;370(1):91–99. doi:https://doi.org/10.1016/j.canlet.2015.10.014.
- Garcia-Villatoro EL, DeLuca JAA, Callaway ES, et al. Effects of high-fat diet and intestinal aryl hydrocarbon receptor deletion on colon carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2020;318(3):G451–G463. doi:https://doi.org/10.1152/ajpgi.00268.2019.
- Cheong JE, Sun L. Targeting the IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy – Challenges and opportunities. Trends Pharmacol Sci. 2018;39(3):307–325. doi:https://doi.org/10.1016/j.tips.2017.11.007.
- Xia Y, Wang D, Zhang N, et al. Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients. J Clin Lab Anal. 2018;32(2):e22263. doi:https://doi.org/10.1002/jcla.22263.
- Dowling P, Hughes DJ, Larkin AM, et al. Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer. Clin Chim Acta. 2015;441:133–141. doi:https://doi.org/10.1016/j.cca.2014.12.005.
- Savas S, Hyde A, Stuckless SN, et al. Serotonin transporter gene (SLC6A4) variations are associated with poor survival in colorectal cancer patients. PLoS One. 2012;7(7):e38953. doi:https://doi.org/10.1371/journal.pone.0038953.
- Barkla DH, Tutton PJ. Influence of histamine and serotonin antagonists on the growth of xenografted human colorectal tumors. J Natl Cancer Inst. 1981;67(6):1207–1212.
- Nocito A, Dahm F, Jochum W, et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 2008;68(13):5152–5158. doi:https://doi.org/10.1158/0008-5472.CAN-08-0202.
- Boursi B, Lurie I, Haynes K, et al. Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients. Eur J Cancer Care. 2018;27(1):e12666. doi:https://doi.org/10.1111/ecc.12666.
- Lee H-C, Chiu W-C, Wang T-N, et al. Antidepressants and colorectal cancer: A population-based nested case-control study. J Affect Disord. 2017;207:353–358. doi:https://doi.org/10.1016/j.jad.2016.09.057.
- Ataee R, Ajdary S, Zarrindast M, et al. Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line. J Cancer Res Clin Oncol. 2010;136(10):1461–1469. doi:https://doi.org/10.1007/s00432-010-0801-3.
- Ataee R, Ajdary S, Zarrindast M, et al. Y25130 hydrochloride, a selective 5HT3 receptor antagonist has potent antimitogenic and apoptotic effect on HT29 colorectal cancer cell line. Eur J Cancer Prev. 2010;19(2):138–143. doi:https://doi.org/10.1097/CEJ.0b013e3283354901.
- Ahmadi AA, Shadifar M, Ataee R, et al. The serotonin 5-HT2A receptor antagonist ritanserin induces apoptosis in human colorectal cancer and acts in synergy with curcumin. Int Biol Biomed J. 2015;1:56–65.
- Sui H, Xu H, Ji Q, et al. 5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway. Oncotarget. 2015;6(28):25975–25987. doi:https://doi.org/10.18632/oncotarget.4543.
- Pan J, Xu Y, Song H, et al. Extracts of Zuo Jin Wan, a traditional Chinese medicine, phenocopies 5-HTR1D antagonist in attenuating Wnt/β-catenin signaling in colorectal cancer cells. BMC Complement Altern Med. 2017;17(1):1–11. doi:https://doi.org/10.1186/s12906-017-2006-7.